GlaxoSmithKline Stock News

An experimental drug for a hard-to-treat bone cancer, being developed by Hansoh Pharmaceutical and GSK, helped patients live longer without ​the disease worsening, according to data presented by researchers at a medical meeting ‌on Monday.

Jefferies has reiterated its 'buy' rating on GSK PLC (LSE:GSK, NYSE:GSK), the pharmaceutical company, with a 2,500p price target after US regulators approved its hepatitis B treatment, Hibsago. The target represents a potential upside of 34% from the 1,868.5p closing price used in the broker's 21 October research note.

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B (CHB) virus infection in combination with nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI) therapy in adult patients without cirrhosis, receiving NrtI therapy for at least 6 months, who hav...

The US FDA said on Tuesday it had approved British drugmaker GSK's hepatitis B drug Hibsago, allowing patients ​with the liver infection a way to keep the virus under ‌control after stopping treatment.

Jefferies rates GSK PLC (LSE:GSK, NYSE:GSK), the FTSE 100 pharmaceutical company, 'buy' with a 2,500p price target, implying 34% upside from Friday's close of 1,862.50p, after global trial results for its experimental cancer drug ris-rez showed a 61% tumour response rate. The EMBOLD study in extensive-stage small-cell lung cancer showed an objective response rate of 61% among patients receiving...

GSK PLC (LSE:GSK, NYSE:GSK) said its experimental lung cancer treatment risvutatug rezetecan produced a 61% confirmed response rate at the higher dose tested in an early-stage global trial of patients with relapsed extensive-stage small cell lung cancer. The FTSE 100 pharmaceutical group said 11 of 18 evaluable patients receiving an 8 milligram per kilogram dose responded to treatment, compared...

GSK to cut up to 1,217 jobs in Belgium, L'Echo says

GSK PLC (LSE:GSK, NYSE:GSK) is expected to deliver a broadly in-line third quarter as weaker vaccine sales are offset by strength in HIV treatments and respiratory drug Nucala, according to RBC Capital Markets. The broker reiterated its Sector Perform rating and 1,975p price target ahead of GSK's results on 28 October, compared with a share price of 1,771p when the note was published.